



UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ley et al.
Serial No.: 09/884,767
Filed: June 19, 2001
Entitled: NOVEL ENTEROKINASE
CLEAVAGE SEQUENCES

Art Unit: 1652

Examiner: PATTERSON, C.

Attorney Docket No.: DYX-012.1 US

Commissioner for Patents
Washington, DC 20231

RECEIVED

APR 17 2003

TECH CENTER 1600/2900

TRANSMITTAL LETTER

Sir:

Transmitted herewith are: [X] a Response under 37 C.F.R. § 1.111; and [X] a return-receipt postcard.

FEE FOR ADDITIONAL CLAIMS

[X] A fee for additional claims is not required.

[] A fee for additional claims is required. The additional fee has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	NUMBER OF EXCESS CLAIMS	RATE	FEE DUE
TOTAL CLAIMS	<u>6</u>	<u>49</u>	<u>0</u>	× \$9	= 0.00
INDEPENDENT	<u>1</u>	<u>3</u>	<u>0</u>	× \$42	= 0.00
FIRST INTRODUCTION OF MULTIPLE DEPENDENT CLAIM				+\$140	= 0.00
TOTAL FEES DUE					= 0.00

[X] Small entity status has been established previously for Applicant(s) in this case.

PETITION FOR EXTENSION OF TIME

[] Extension is requested under 37 CFR 1.136(a), and the following extension fee is applicable for the paper(s) filed herewith:

- [] \$55.00 for response within first month pursuant to 37 CFR 1.17(a)(1);
- [] \$205.00 for response within second month pursuant to 37 CFR 1.17(a)(2);
- [] \$465.00 for response within third month pursuant to 37 CFR 1.17(a)(3);
- [] \$725.00 for response within fourth month pursuant to 37 CFR 1.17(a)(4);
- [] \$985.00 for response within fifth month pursuant to 37 CFR 1.17(a)(5).

☐ A check in the amount of ☐ \$55.00 ☐ \$205.00 ☐ \$465.00 ☐ \$725.00 ☐ \$985.00 in payment of the extension fee is transmitted herewith. {check no. }

☐ Please charge the requisite fee of ☐ \$55.00 ☐ \$205.00 ☐ \$465.00 ☐ \$725.00 ☐ \$985.00 in payment of the additional extension fee to Deposit Account No. 50-0268.

OTHER FEES

☐ A check in the amount of \$130.00 in payment of the oath or declaration surcharge fee under 37 C.F.R. § 1.16(e) is transmitted herewith. {check no. }

☒ The Commissioner is hereby authorized to charge payment of any additional fees required in connection with the paper(s) and enclosures transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 50-0268. A duplicate of this transmittal letter is enclosed.

Respectfully submitted,



Leon R. Yankwich, Reg. No. 30,237
Michael R. Wesolowski, Reg. No. 50,944
Attorney/Representative for Applicant(s)
YANKWICH & ASSOCIATES
201 Broadway
Cambridge, MA 02139
tel.: (617) 374-3700
fax: (617) 374-0055

RECEIVED


APR 17 2003

TECH CENTER 1600/2900

CERTIFICATE OF MAILING

The undersigned hereby certifies that this correspondence listed above is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 C.F.R. §1.10, postage prepaid, Express Mailing Label No. **EV 190444776 US**, in an envelope address to the Commissioner for Patents, Washington, D.C. 20231 on the date indicated below.

April 14, 2003
date of mailing


Michael R. Wesolowski, Reg. No. 50,944



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: LEY et al.

Serial No.: 09/884,767

Filed: June 19, 2001

Entitled: NOVEL ENTEROKINASE CLEAVAGE
SEQUENCES

ART UNIT: 1652

EXAMINER: PATTERSON, C.

Attorney Docket No.: DYX-012.1 US

Commissioner for Patents
Washington, D.C. 20231

RECEIVED

APR 17 2003

TECH CENTER 1600/2900

AMENDMENT AND RESPONSE

Sir:

This paper is filed in response to the Office Action (paper no. 11), mailed January 13, 2003 in the above-identified patent application. In accordance with 37 C.F.R. §1.111, please enter and consider the following amendments and remarks, which are intended to put this application into condition for allowance.

IN THE CLAIMS

Pursuant to the amendment procedure set forth in 1267 OG 106, please substitute each amended claim appearing in Appendix A for the pending claim with the same number. Pursuant to the revised amendment format guidelines, Applicants submit a single copy of all pending claims, with markings to show changes made and status identifiers (see Appendix A).

Please cancel non-elected Claims 8-49, without prejudice to their introduction in an application claiming the benefit of this application under 35 U.S.C. §120/121. Additionally, please cancel Claims 3, 6, and 7, and amend Claims 1, 2, and 4 as indicated. Also, please add new Claims 50 and 51.